Meta‐analysis: targeting the intestinal microbiota in prophylaxis for post‐operative Crohn’s disease

• Published in: Alimentary pharmacology & therapeutics Vol. 31; no. 8; pp. 802 - 809
• Main Authors: DOHERTY, G. A., BENNETT, G. C., CHEIFETZ, A. S., MOSS, A. C.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-04-2010; Blackwell
• Subjects: Anti-Bacterial Agents - therapeutic use; Antibiotic Prophylaxis - methods; Biological and medical sciences; Crohn Disease - drug therapy; Digestive system; Enterobacteriaceae Infections - prevention & control; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Medical sciences; Nitroimidazoles - therapeutic use; Other diseases. Semiology; Pharmacology. Drug treatments; Postoperative Complications - prevention & control; Probiotics - therapeutic use; Randomized Controlled Trials as Topic; Secondary Prevention; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Postoperative; Prevention; Crohn disease; Target; Targeting; Digestive system; Gut; Digestive diseases; Intestinal disease; Microflora; Inflammatory disease; Metaanalysis
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2010.04231.x

Aliment Pharmacol Ther 31, 802–809
Summary
Background  Enteric bacteria play an important early role in the pathogenesis of Crohn’s disease.
Aim  To perform a meta‐analysis of trials testing antibiotics or probiotics for prevention of post‐operative recurrence of Crohn’s disease.
Methods  Review of all randomized controlled trials comparing antibiotics or probiotics with placebo in prevention of endoscopic or clinical recurrence of Crohn’s disease after surgical resection. Fixed‐effect meta‐analysis was performed with dichotomous data summarized using relative risk with 95% confidence intervals, where appropriate.
Results  Seven studies were identified as suitable for inclusion (two comparing antibiotics with placebo, five comparing probiotics with placebo). The use of nitroimidazole antibiotics (metronidazole, ornidazole) reduced the risk of clinical (RR 0.23; 95% CI 0.09–0.57, NNT = 4) and endoscopic (RR 0.44; 95% CI 0.26–0.74, NNT = 4) recurrence relative to placebo. However, these agents were associated with higher risk of adverse events (RR 2.39, 95% CI 1.5–3.7) and patient withdrawal. Probiotic administration was not associated with any significant difference in risk of recurrence compared with placebo.
Conclusions  Nitroimidazole antibiotics are effective in the prevention of post‐operative Crohn’s disease recurrence, but their side‐effects limit acceptability. Probiotics have failed to show efficacy for post‐operative prophylaxis, but may merit further study.